Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest’s Fetzima Will Test Enantiomer Exclusivity Policy Change

Executive Summary

The antidepressant levomilnacipran, an enantiomer of Forest’s fibromyalgia drug Savella (milnacipran), could be the first product to take advantage of an FDA Amendments Act provision that allows enantiomers of previously approved drugs to qualify for five years of new chemical entity exclusivity.

You may also be interested in...



Additional Cariprazine Trial Could Put Forest In A Better Competitive Position

FDA “complete response” letter seeks another trial to better define the most tolerable dose, which could get the atypical antipsychotic to market in a better position than the original dataset.

Deals Of The Week Looks At Pricing Conundrums

New therapeutic modalities can bring unexpected challenges in pricing, as uniQure and electroCore learn. Also, deal news from Celgene/OncoMed, Forest/Merck, Theraclone/PharmAthene, The Medicines Company/Rempex and Roche/Molecular Partners.

Forest Cuts A New Path But Remains Rooted In Primary Care

Forest’s new CEO outlined “Project Rejuvenate,” a strategy to recharge the drug marketer, Dec. 2. The program involves headcount and cost reductions and the sale of $1 billion in debt to fund share repurchases and bolt-on acquisitions. But the plan doesn’t call for a change in strategic direction since Saunders intends to strengthen Forest’s commitment to primary care.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS055514

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel